Daptomycin treatment in patients with resistant staphylococcal periprosthetic joint infection

BMC Infectious Diseases

Table 2 Information regarding patients’ infections and daptomycin usage

Patients	Surgical procedure	Pathogen	DAP Reason	DAP dosage (mg/kg/day)	DAP duration (days)	Total parental antibiotics (days)	Total time under DAP (%)	Adverse effects	Outcome	Follow-up (months)
1	two-stage reimplantation	MRSA	intolerance	10	10	13	77	none	success	26
2	two-stage reimplantation	MRSA	intolerance	8.3	18	35	51	none	success	27
3	two-stage reimplantation	MRCoNS	CKD stage 5	3.3	12	15	80	none	success	25
4	DAIR	MRCoNS	intolerance	8.3	23	23	100	none	success	41
5	two-stage reimplantation	MRSA	CKD stage 3	7.7	13	13	100	none	success	23
6	DAIR	MRSA	teicoplanin failure	10.6	11	21	52	AST elevation	success	25
7	two-stage reimplantation	MRCoNS	intolerance	8.3	12	26	46	none	success	27
8	two-stage reimplantation	MRSA	intolerance	7.2	18	49	37	none	success	24
9	DAIR	MRSA	vancomycin MIC >1.5 mg/L	10	27	32	84	none	success	26
10	two-stage reimplantation	MRSA	empirical	6.3	21	33	64	none	failure	24
11	two-stage reimplantation	MRCoNS	intolerance	10	13	36	36	none	success	34
12	two-stage reimplantation	MRSA	teicoplanin failure	6.7	14	39	36	none	success	36
13	DAIR	MRSA	intolerance	7.4	14	20	70	none	success	29
14	two-stage reimplantation	MRCoNS	empirical	8.3	16	22	73	none	success	36
15	DAIR	MRSA	empirical	8.3	26	66	39	none	failure	34
16	two-stage reimplantation	MRCoNS	empirical	10.6	11	19	58	none	success	42

DAP Daptomycin, MRSA Methicillin-resistant Staphylococcus aureus, MRCoNS Methicillin-resistant coagulase-negative staphylococci CKD, chronic kidney disease, MIC Minimum inhibitory concentration, AST Aspartate aminotransferase; intolerance, allergy to glycopeptide or phlebitis

ISSN: 1471-2334